May 14, 2024 IntegriChain Expert to Speak on Best Price Stacking Impacts at Informa Pricing and Contracting USA Jeff Baab, Vice President of Advisory Services, will speak at Informa’s Pricing and Contracting USA conference. The session will focus on forecasting impacts of best price stacking. The hybrid conference runs May 21-23 in New Orleans, Louisiana.
April 9, 2024 Registration Opens for Access Insights Conference 2024 Co-Hosted by IntegriChain and Blue Fin Group Registration is open for the Access Insights Conference 2024, October 14-16 in Washington, DC, and co-hosted with Blue Fin Group. Designed for commercial, operational, and financial teams at pharma manufacturers, the conference will feature industry panels, healthcare policy and financial experts, and strategic and tactical best practices for data-driven patient access and therapy commercialization.
February 28, 2024 Longtime Gilead Commercial Executive Joins IntegriChain as Chairman of the Board IntegriChain appoints Jim Meyers, a highly experienced pharmaceutical commercialization executive, as Chairman of the Board. Meyers offers more than 35 years of industry experience, from his more than two decades at Gilead Sciences where he served as Chief Commercial Officer and EVP of Worldwide Commercial Operations to his leadership in emerging biopharma as a board member for a broad spectrum of clinical-stage companies.
January 2, 2024 IntegriChain Appoints Seasoned Executive to Lead Data Business for Pharma Distribution and Patient Access IntegriChain appoints Jeff Uccello as Senior Vice President and General Manager of Data Solutions. Uccello is a seasoned pharma data executive with more than 20 years of experience across a wide range of commercialization data and analytics and business leadership roles.
December 19, 2023 IntegriChain Announces Close of Nordic Capital Majority Investment IntegriChain announces close of Nordic Capital majority investment Investment, which will accelerate IntegriChain’s ambitious growth targets and cement its status as a leading commercialization platform for pharma manufacturers.
December 5, 2023 IntegriChain and Blue Fin Group Pharma Trade and Distribution Experts to Speak at Informa Trade & Channel Strategies IntegriChain pharmaceutical strategy expert Bill Roth, General Manager and Managing Partner, Blue Fin Group will be the keynote speaker at Informa’s Trade & Channel Strategies conference. In addition, distribution experts David Weiss, IntegriChain Vice President of Industry Solutions, and Jason Bogroff, Blue Fin Group Partner, will speak at the event.
November 30, 2023 IntegriChain GTN Experts to Speak at Informa’s Pharma/BioTech GTN Summit Philadelphia, PA, November 13, 2023 – IntegriChain, delivering pharma’s only comprehensive technology, data, consulting, and outsourcing platform for data-driven commercialization, today announced that its Gross-to-Net (GTN) experts will present at Informa’s upcoming Pharma | Biotech GTN Summit. Jen Sharpe, Vice President of Gross-to-Net Operational Consulting and facilitator of the Revenue Analytics Collaborative, and Jeff Baab, Vice President of Operational Consulting, have extensive experience in GTN automation, advising Pharma manufacturers of all sizes, business stages, and complexity on SaaS and BPaaS solutions for GTN forecasting, accruals, and analytics. Jen Sharpe is Chairperson and IntegriChain is a sponsor of the conference, which […]
November 8, 2023 Nordic Capital acquires majority share in IntegriChain, the only fully integrated platform for pharma commercialization and market access Nordic Capital has signed an agreement to acquire a majority share in IntegriChain. Nordic Capital is acquiring the majority stake from Accel-KKR, a global software private equity firm, which first invested in IntegriChain in 2016.
November 7, 2023 IntegriChain Presents The Tina Patel Shining Light Award to Patrick Townsend of Vertex Pharmaceuticals IntegriChain presents customer awards to Patrick Townsend of Vertex as well as Johnson & Johnson Innovative Medicine, Alexion Pharmaceuticals, and Tarsus Pharmaceuticals.
